Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain MetastasesAnna Maria Di Giacomo, Michele Maio, Luana Calabrò et al.|Clinical Cancer Research|2021Cited by 75
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trialAnna Maria Di Giacomo, Michele Maio, Vanna Chiarion‐Sileni et al.|European Journal of Cancer|2024Cited by 39
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national databaseFrancesco Panzuto, Massimo Falconi, Stefano Partelli et al.|Endocrine|2024Cited by 19
Long-term follow up of patients affected by pulmonary carcinoid at the Istituto Nazionale Tumori of Milan: a retrospective analysis.Sara Pusceddu, Emilio Bajetta, Laura Catena et al.|PubMed|2010Cited by 16
1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trialAnna Maria Di Giacomo, Michele Maio, Michele Del Vecchio et al.|Annals of Oncology|2020Cited by 7